Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Long

Showing results (21-30 of 1,614) with videos related to

Pageof 162
Sort By:
Expert Review of Clinical Pharmacology|November 13, 2015
Safety and efficacy of targeted agents monotherapy in advanced NSCLCQi Zhang, Yi-Long Wu
Sheng Li Xue Bao : [Acta Physiologica Sinica]|October 31, 2025
[Research progress on the role of extracellular vesicles in the repair of skeletal muscle membrane injury]Yi-Long Liu, Ying Wu
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi = Chinese Journal of Parasitology & Parasitic Diseases|April 20, 2016
[Research Progress on Artemisinin Resistance in Plasmodium falciparum]Yi-long Zhang, Wei-qing Pan
Talanta|April 20, 2013
A new sensitive and selective fluorescence probe for detection of cyanideYi-Long Duan, Yan-Song Zheng
Journal of Global Oncology|July 19, 2017
Misuse of Pirated Drugs: Why China? What Is Next?Hui-Wen Sun, Yi-Long Wu
Chinese Journal of Cancer|July 12, 2015
Insight into early-phase trials for lung cancer in the United StatesJin-Ji Yang, Yi-Long Wu
Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA|February 13, 2003
[Value of serum progesterone for ectopic pregnancy in therapeutic effect monitoring]Jiang-tao Fan, Feng-yi Long
Organic Letters|May 25, 2007
Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinasesYi-Long Yan, Seth M Cohen
The Lancet. Oncology|January 6, 2018
Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' replyYi-Long Wu, Tony S Mok
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2021
Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase InhibitorsJia-Tao Zhang, Yi-Long Wu
Pageof 162

Showing results (21-30 of 1,614) with videos related to

Sort By:
Pageof 162
Expert Review of Clinical Pharmacology|November 13, 2015
Safety and efficacy of targeted agents monotherapy in advanced NSCLCQi Zhang, Yi-Long Wu
Sheng Li Xue Bao : [Acta Physiologica Sinica]|October 31, 2025
[Research progress on the role of extracellular vesicles in the repair of skeletal muscle membrane injury]Yi-Long Liu, Ying Wu
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi = Chinese Journal of Parasitology & Parasitic Diseases|April 20, 2016
[Research Progress on Artemisinin Resistance in Plasmodium falciparum]Yi-long Zhang, Wei-qing Pan
Talanta|April 20, 2013
A new sensitive and selective fluorescence probe for detection of cyanideYi-Long Duan, Yan-Song Zheng
Journal of Global Oncology|July 19, 2017
Misuse of Pirated Drugs: Why China? What Is Next?Hui-Wen Sun, Yi-Long Wu
Chinese Journal of Cancer|July 12, 2015
Insight into early-phase trials for lung cancer in the United StatesJin-Ji Yang, Yi-Long Wu
Di 1 Jun Yi Da Xue Xue Bao = Academic Journal of the First Medical College of PLA|February 13, 2003
[Value of serum progesterone for ectopic pregnancy in therapeutic effect monitoring]Jiang-tao Fan, Feng-yi Long
Organic Letters|May 25, 2007
Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinasesYi-Long Yan, Seth M Cohen
The Lancet. Oncology|January 6, 2018
Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' replyYi-Long Wu, Tony S Mok
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2021
Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase InhibitorsJia-Tao Zhang, Yi-Long Wu
Pageof 162